Skip to content

Stereotaxis STXS Deferred Tax Assets, Gross

Deferred Tax Assets, Gross at other companies

Abbott logo
AbbottABT
Neuropace, Inc. logo
Neuropace, Inc.NPCE

Other financials

Income statement

See full
Revenue$6.3M-15.8%
Gross profit$3.8M-6.6%
Operating income-$6.0M-0.9%
Net income-$5.9M-0.7%
EPS (diluted)-$0.06+14.3%

Balance sheet

See full
Cash & equivalents$14.6M+36.7%
Total debt$5.3M-10.0%
Total equity$14.4M+399%
Total assets$54.0M+18.2%

Cash flow

See full
Operating cash flow-$3.4M-93.5%
CapEx$79.0K
Free cash flow-$3.5M

Valuation

See full
Market cap$168.11M-11.6%
Enterprise value$158.77M-15.9%
P/S5.4×-0.6×

Profitability

See full
Gross margin53.9%+0.5pp
Operating margin-71%-14.0pp
Net margin-69.5%-13.7pp
FCF margin-35.5%-2.4pp

Returns & leverage

See full
Return on equity-251.5%-29.9pp
Debt / equity0.4×-1.7×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsGross.

The official record: Stereotaxis’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's deferred tax assets, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stereotaxis's deferred tax assets, gross?
Stereotaxis (STXS) reported deferred tax assets, gross of $43.33M in Q4 2025.
How has Stereotaxis's deferred tax assets, gross changed year-over-year?
Stereotaxis's deferred tax assets, gross increased by 4.3% year-over-year, from $41.52M to $43.33M.
What is the long-term trend for Stereotaxis's deferred tax assets, gross?
Over 5 years (2020 to 2025), Stereotaxis's deferred tax assets, gross has grown at a 8.4% compound annual growth rate (CAGR), from $28.97M to $43.33M.